Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8753665 | DURECT | Controlled delivery system |
Sep, 2025
(1 year, 11 months from now) | |
US8846072 | DURECT | Controlled delivery system |
Sep, 2025
(1 year, 11 months from now) | |
US8153661 | DURECT | Controlled delivery system |
Sep, 2025
(1 year, 11 months from now) | |
US8153149 | DURECT | Controlled delivery system |
Sep, 2025
(1 year, 11 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Feb 1, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 01 February, 2021
Treatment: Method for providing sustained local anesthesia for at least 24 hours
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic